Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Amphastar Pharmaceuticals, Inc. or Organon & Co. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Amphastar Pharmaceuticals, Inc. and Organon & Co. compare based on key financial metrics to determine which better meets your investment needs.

About Amphastar Pharmaceuticals, Inc. and Organon & Co.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Latest Pharmaceuticals and Amphastar Pharmaceuticals, Inc., Organon & Co. Stock News

As of September 2, 2026, Amphastar Pharmaceuticals, Inc. had a $1.0 billion market capitalization, compared to the Pharmaceuticals median of $674.0 million. Amphastar Pharmaceuticals, Inc.’s stock is down 12.2% in 2026, up 7.4% in the previous five trading days and down 22.95% in the past year.

Currently, Amphastar Pharmaceuticals, Inc.’s price-earnings ratio is 14.1. Amphastar Pharmaceuticals, Inc.’s trailing 12-month revenue is $730.0 million with a 10.8% net profit margin. Year-over-year quarterly sales growth most recently was 5.4%. Analysts expect adjusted earnings to reach $2.972 per share for the current fiscal year. Amphastar Pharmaceuticals, Inc. does not currently pay a dividend.

As of September 2, 2026, Organon & Co. had a $3.6 billion market cap, putting it in the 62nd percentile of all stocks. Organon & Co.’s stock is up 92% in 2026, NA 0% in the previous five trading days and up 46.18% in the past year.

Currently, Organon & Co.’s price-earnings ratio is 17.4. Organon & Co.’s trailing 12-month revenue is $6.1 billion with a 3.4% net profit margin. Year-over-year quarterly sales growth most recently was -2.3%. Analysts expect adjusted earnings to reach $3.336 per share for the current fiscal year. Organon & Co. currently has a 0.6% dividend yield.

How We Compare Amphastar Pharmaceuticals, Inc. and Organon & Co. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Amphastar Pharmaceuticals, Inc. and Organon & Co.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Amphastar Pharmaceuticals, Inc. and Organon & Co. Stock Value Grades

Company	Ticker	Value
Amphastar Pharmaceuticals, Inc.	AMPH	A
Organon & Co.	OGN	B

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Amphastar Pharmaceuticals, Inc. has a Value Score of 90, which is Deep Value. Organon & Co. has a Value Score of 71, which is Value.

The Value Stock Winner: Amphastar Pharmaceuticals, Inc.

As you can clearly see from the Value Grade breakdown above, Amphastar Pharmaceuticals, Inc. is considered to have better value than Organon & Co.. For investors who focus solely on a company’s valuation, Amphastar Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Amphastar Pharmaceuticals, Inc. and Organon & Co. Growth Grades

Company	Ticker	Growth
Amphastar Pharmaceuticals, Inc.	AMPH	A
Organon & Co.	OGN	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Amphastar Pharmaceuticals, Inc. has a Growth Score of 82, which is Very Strong. Organon & Co. has a Growth Score of 25, which is Weak.

The Growth Grade Winner: Amphastar Pharmaceuticals, Inc.

As you can clearly see from the Growth Grade breakdown above, Amphastar Pharmaceuticals, Inc. has a more attractive growth grade than Organon & Co.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Amphastar Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Amphastar Pharmaceuticals, Inc. and Organon & Co.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Amphastar Pharmaceuticals, Inc.	AMPH	B
Organon & Co.	OGN	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Amphastar Pharmaceuticals, Inc. has a Earnings Estimate Score of 62, which is Positive. Organon & Co. has a Earnings Estimate Score of 19, which is Very Negative.

The Earnings Estimate Revisions Grade Winner: Amphastar Pharmaceuticals, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Amphastar Pharmaceuticals, Inc. has a better Earnings Estimate Revisions Grade than Organon & Co.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Amphastar Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Amphastar Pharmaceuticals, Inc. and Organon & Co. Grades

In addition to Estimate Revisions, Value and Growth, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Amphastar Pharmaceuticals, Inc. and Organon & Co. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Amphastar Pharmaceuticals, Inc. or Organon & Co. Stock?

Overall, Amphastar Pharmaceuticals, Inc. stock has a Value Score of 90, Growth Score of 82 and Estimate Revisions Score of 62.

Organon & Co. stock has a Value Score of 71, Growth Score of 25 and Estimate Revisions Score of 19.

Comparing Amphastar Pharmaceuticals, Inc. and Organon & Co.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.